Document is current

Article History

Received: 3 January 2022

Accepted: 24 March 2022

First Online: 5 April 2022

Declarations

:

: All clinical, radiological, and laboratory data were collected after obtaining approval by the local Ethics Committee of Istituto Tumori “Giovanni Paolo II” of Bari (prot. nb. 779, July 23rd, 2019) and by the Ethics Committee of each participant Centre, according to the international standards of good clinical practice. All medical data used in this study were irreversibly anonymized.

: Informed consent was obtained from all the patients enrolled in the study.

: Michele Guida: advisory role for Bristol Myers Squibb, Merck Sharp & Dohme, Novartis, Pierre Fabre; Pietro Quaglino: speaker fees e advisory boards for BMS, MSD, Pierre-Fabre, Novartis, Roche; Anna Maria Di Giacomo: advisory role for Bristol Myers Squibb, Merck Sharp & Dohme, GSK, Pierre Fabre, Sanofi; Alessandro Marco Minisini: advisory board for Novartis, MSD, Pierre Fabre; Francesco Spagnolo: Honoraria: BMS, Roche, Novartis, MSD, Sanofi, Merck, Sunpharma, Pierre-Fabre. Advisory Board: MSD, Novartis, Sunphama, Pierre Fabre; Marcella Occelli: Speaker role for Bristol Myers Squibb, Merck Sharp & Dohme, Novartis, Roche; Paola Queirolo: advisory and consultant role for Roche, BMS, Merck, MSD, Novartis, Pierre Fabre, Sun Pharma, Sanofi; Paolo Antonio Ascierto: consultant/advisory role for Bristol Myers-Squibb, Roche-Genentech, Merck Sharp & Dohme, Array, Novartis, Merck Serono, Pierre Fabre, Incyte, NewLink Genetics, Genmab, Medimmune, AstraZeneca, Syndax, SunPharma, Sanofi, Idera, Ultimovacs, Sandoz, Immunocore, 4SC, Alkermes, Italfarmaco, Nektar, Boehringer-Ingelheim. He also received research funds from Bristol Myers-Squibb, Roche-Genentech, Array, and travel support from MSD; Vanna Chiaron Sileni: Travel support for medical congress for Bristol Myers-Squibb, lectures fees and Advisory Board for Merck Sharp & Dohme, participation to advisory board for Novartis, Pierre Fabre.